DOCSLIB.ORG

Multiple Sclerosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Multiple Sclerosis Annals of Internal MedicineT In the ClinicT Multiple Sclerosis any groundbreaking advances have Diagnosis occurred in the field of multiple sclerosis Msince this series last reviewed the disorder in 2014. The U.S. Food and Drug Administration Treatment has approved 7 new medications for relapsing– remitting multiple sclerosis and approved the first medication for primary progressive multiple sclero- sis. The McDonald criteria for diagnosing multiple COVID-19 and sclerosis were updated in 2017. New blood tests can now differentiate patients with multiple sclero- Multiple Sclerosis sis from those with neuromyelitis optica spectrum disorder, and 3 new medications have been app- roved specifically for the latter disorder. Also, new medications for treating the symptoms of multiple sclerosis have been introduced. CME/MOC activity available at Annals.org. Physician Writer doi:10.7326/AITC202106150 Michael J. Olek, DO Touro University Nevada, This article was published at Annals.org on 8 June 2021. Henderson, Nevada CME Objective: To review current evidence for diagnosis and treatment of multiple sclerosis. Funding Source: American College of Physicians. Acknowledgment: The author thanks Daniel M. Harrison, MD, author of the previous version of this In the Clinic. Disclosures: Dr. Olek, ACP Contributing Author, reports that he is the first author of the chapter on multiple sclerosis in UpToDate. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21- 0830. With the assistance of additional physician writers, the editors of Annals of Internal Medicine develop In the Clinic using MKSAP and other resources of the American College of Physicians. The patient information page was written by Monica Lizarraga from the Patient and Interprofessional Partnership Initiative at the American College of Physicians. In the Clinic does not necessarily represent official ACP clinical policy. For ACP clinical guidelines, please go to https://www.acponline.org/clinical_information/ guidelines/. © 2021 American College of Physicians Multiple sclerosis is an autoim- concordance rates between 20% 1. Wallin MT, Culpepper WJ, mune condition that results in and 30% in monozygotic twins Campbell JD, et al; US inflammatory damage to the cen- and between 2% and 3% in dizy- Multiple Sclerosis Prevalence Workgroup. The tral nervous system (CNS). The gotic twins (2). Genome-wide prevalence of MS in the fi United States: a popula- pathologic hallmarks are diffuse assays have identi ed risk alleles tion-based estimate using and focal areas of inflammation, in the genes for major histocom- health claims data. Neurology. 2019;92: demyelination, gliosis, and neuro- patibility complex, interleukin-2 e1029-e1040. [PMID: nal injury in the optic nerves, receptor, and interleukin-7 recep- 30770430] 2. Islam T, Gauderman WJ, brain, and spinal cord. In addition tor, among others (3,4). Geo- Cozen W, et al. Differential twin concordance for multi- to affecting white matter tracts, graphic location of residence ple sclerosis by latitude of multiple sclerosis results in injury birthplace. Ann Neurol. before adolescence also predicts 2006;60:56-64. [PMID: to the cortical and deep gray mat- risk, with increased rates in north- 16685699] ter. The neurologic symptoms and 3. Patsopoulos NA, Barcellos ern and southern latitudes com- LF, Hintzen RQ, et al; disability that patients experience pared with equatorial areas. This IMSGC. Fine-mapping the are a direct consequence of these genetic association of the may be related to the observation major histocompatibility pathologic processes, resulting in complex in multiple sclero- that persons with vitamin D defi- sis: HLA and non-HLA acute and chronic disruption of effects. PLoS Genet. white matter tracts and gray mat- ciency seem to have increased 2013;9:e1003926. [PMID: 24278027] ter structures. risk for multiple sclerosis. Because 4. Beecham AH, Patsopoulos ultraviolet radiation to the skin is NA, Xifara DK, et al; Multiple sclerosis is the most com- International Multiple the major source of vitamin D syn- Sclerosis Genetics mon nontraumatic cause of neuro- Consortium (IMSGC). thesis, vitamin D deficiency is Analysis of immune-related logic disability in persons younger loci identifies 48 new sus- than 40 years. In 2010, the esti- more common among persons ceptibility variants for mul- tiple sclerosis. Nat Genet. mated prevalence in the United living in regions with low levels of 2013;45:1353-60. [PMID: seasonal sunlight (5). Risk may 24076602] States was 309.2 per 100 000 per- 5. Sintzel MB, Rametta M, sons, or 727 433 adults (1). It also be influenced by exposure or Reder AT. Vitamin D and – multiple sclerosis: a com- occurs in a female male ratio of lack of exposure to infectious prehensive review. Neurol 2.8 to 1 (1). agents because antibodies Ther. 2018;7:59-85. [PMID: 29243029] The cause of multiple sclerosis is against certain viruses, such as 6. Lassmann H, Niedobitek G, – Aloisi F, et al; multifactorial and is probably the Epstein Barr virus, are more fre- NeuroproMiSe EBV Working Group. Epstein– cumulative result of multiple quently seen in patients with mul- Barr virus in the multiple tiple sclerosis than in those sclerosis brain: a controver- genetic and environmental risk sial issue—report on a factors. Studies have shown without it (6). focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain. 2011;134:2772-86. [PMID: Diagnosis 21846731] 7. de la Cruz J, Kupersmith What characteristic symptoms clinical presentations vary widely. MJ.. Clinical profile of fi The most common initial clinical simultaneous bilateral or physical ndings should optic neuritis in adults. Br J alert clinicians to the diagnosis manifestations are the result of Ophthalmol. 2006;90:551- fl 4. [PMID: 16622084] of multiple sclerosis? in ammation of the optic nerve 8. Thompson AJ, Banwell BL, (optic neuritis), focal inflammation Barkhof F, et al. Diagnosis Symptoms typically occur as a within the spinal cord (myelitis), of multiple sclerosis: 2017 consequence of focal inflamma- revisions of the McDonald and brainstem or cerebellar criteria. Lancet Neurol. tory plaques that cause functional 2018;17:162-73. [PMID: lesions. Each of these is termed a 29275977] areas of neuronal loss or interrup- 9. O’Riordan JI, Thompson AJ, tion of critical axonal tracts. In clinically isolated syndrome (CIS). Kingsley DP, et al. The prognostic value of brain most patients, focal lesions occur Optic neuritis often presents with MRI in clinically isolated intermittently and acutely, leading subacute vision changes that vary syndromes of the CNS. A “ ” “fl ” 10-year follow-up. Brain. to a relapse or are in which from blindness to a central sco- 1998;121:495-503. [PMID: symptoms evolve over the course toma or a horizontal oval scotoma 9549525] of days and may last for weeks or 10. Weinshenker BG, Bass B, embracing both the fixation point Rice GP, et al. The natural months before improving, if they history of multiple sclero- do improve. and the blind spot (centrocecal sis: a geographically — based study. I. Clinical scotoma) predominantly in 1 eye course and disability. Because multiple sclerosis can (90%) and rarely in both eyes Brain. 1989;112:133-46. [PMID: 2917275] affect nearly any part of the CNS, (10%)—along with pain during eye © 2021 American College of Physicians ITC2 In the Clinic Annals of Internal Medicine movement (7). Ocular examina- Oculomotor examination can also 11. Kremenchutzky M, Rice tion usually reveals a reduction in find disconjugate eye movements, GP, Baskerville J, et al. fi fi nystagmus, or an inability to The natural history of visual acuity, a visual eld de cit, multiple sclerosis: a and a decreased ability to differ- adduct 1 eye with nystagmus in geographically based study 9: observations on entiate colors. Examination of the the abducting eye (internuclear the progressive phase of ophthalmoplegia). the disease. Brain. pupil in patients with unilateral 2006;129:584-94. optic neuritis reveals paradoxical [PMID: 16401620] In addition to the development 12. Filippi M, Rocca MA, dilation of the pupil in the affected of acute or subacute focal symp- Ciccarelli O, et al; MAGNIMS Study Group. eye when light is rapidly and toms, patients with multiple scle- MRI criteria for the diag- repeatedly shifted from one eye nosis of multiple sclero- rosis may have chronic symptoms sis: MAGNIMS to the other (afferent pupillary due to widespread cortical demy- consensus guidelines. Lancet Neurol. defect). If the anterior portion of elination and global brain atro- 2016;15:292-303. the optic nerve is involved, fundu- [PMID: 26822746] phy. Common manifestations 13. Bakshi R, Thompson AJ, scopic examination may also include cognitive dysfunction and Rocca MA, et al. MRI in multiple sclerosis: cur- reveal inflammatory changes of mental and physical fatigue. rent status and future the optic disc (papillitis). prospects. Lancet Many patients with multiple scle- Neurol. 2008;7:615-25. [PMID: 18565455] Myelitis usually manifests as sen- rosis also have transient worsen- 14. Stangel M, Fredrikson S, Meinl E, et al. The utility sory or motor symptoms below ing of baseline neurologic of cerebrospinal fluid the affected spinal level, and ex- symptoms when body tempera- analysis in patients with multiple sclerosis. Nat amination often reveals focal mus- ture is elevated (Uhthoff phenom- Rev Neurol. enon) because electrical 2013;9:267-76. [PMID: cle weakness and reduced 23528543] sensation in the
Load more

Recommended publications
  • Childhood Cerebral X-Linked Adrenoleukodystrophy with Atypical Neuroimaging Abnormalities and a No…
    9/28/2018 Journal of Postgraduate Medicine: Childhood cerebral X-linked adrenoleukodystrophy with atypical neuroimaging abnormalities and a no… Open access journal indexed with Index Medicus & EMBASE Home | Subscribe | Feedback [Download PDF] CASE REPORT Year : 2018 | Volume : 64 | Issue : 1 | Page : 59-63 Childhood cerebral X-linked adrenoleukodystrophy with atypical neuroimaging abnormalities and a novel mutation M Muranjan1, S Karande1, S Sankhe2, S Eichler3, 1 Department of Pediatrics, Seth GS Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, India 2 Department of Radiology, Seth GS Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, India 3 Centogene AG, Schillingallee 68, Rostock, Germany Correspondence Address: Dr. M Muranjan Department of Pediatrics, Seth GS Medical College and KEM Hospital, Parel, Mumbai, Maharashtra India Abstract Childhood cerebral X-linked adrenoleukodystrophy (XALD) typically manifests with symptoms of adrenocortical insufficiency and a variety of neurocognitive and behavioral abnormalities. A major diagnostic clue is the characteristic neuroinflammatory parieto-occipital white matter lesions on magnetic resonance imaging. This study reports a 5-year 10-month old boy presenting with generalized skin hyperpigmentation since 3 years of age. Over the past 9 months, he had developed right-sided hemiparesis and speech and behavioral abnormalities, which had progressed over 5 months to bilateral hemiparesis. Retrospective analyses of serial brain magnetic resonance images revealed an unusual pattern of lesions involving the internal capsules, corticospinal tracts in the midbrain and brainstem, and cerebellar white matter. The clinical diagnosis of childhood cerebral adrenoleukodystrophy was confirmed by elevated basal levels of adrenocorticotropin hormone and plasma very long chain fatty acid levels. Additionally, sequencing of the ABCD1 gene revealed a novel mutation.
    [Show full text]
  • Neuromyelitis Optica Spectrum Disorder
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Review with New Drug Evaluation: Biologics for Autoimmune Disorders-Neuromyelitis Optica Spectrum Disorder Date of Review: April 2021 Date of Last Review: n/a Dates of Literature Search: 1/1/1996 – 1/20/2021 Generic Name: Brand Name (Manufacturer): Eculizumab Soliris® (Alexion Pharmaceuticals) Inebilizumab-cdon Uplizna™ (Viela Bio) Satralizumab-mwge Enspryng™ (Genentech/Roche) Dossiers Received: Yes Current Status of PDL Class: See Appendix 1. Purpose for Class Update: To define place in therapy for 3 immunosuppressive agents, eculizumab, inebilizumab-cdon, and satralizumab-mwge, recently approved by the Food and Drug Administration (FDA) for the treatment adults with neuromyelitis optica spectrum disorder (NMOSD). Research Questions: 1. What is the effectiveness of eculizumab, inebilizumab, and satralizumab in reducing time to relapse in adult patients with NMOSD who are anti-aquaporin-4 (AQP4) antibody positive? 2. What are the harms of eculizumab, inebilizumab-cdon and satralizumab in adults with NMOSD? 3. Is there comparative evidence that eculizumab, inebilizumab, and satralizumab differ in efficacy or harms for management of NMOSD? 4. Are there certain sub-populations (based on age, gender, ethnicity, comorbidities, disease duration or severity) in which eculizumab, inebilizumab, or satralizumab may be beneficial
    [Show full text]
  • Neuromyelitis Optica News
    Neuromyelitis Optica News Gloria von Geldern, MD Assistant Professor of Neurology University of Washington Multiple Sclerosis Center Multiple Sclerosis Regional Summit June 13, 2020 Disclosures ▪ No conflict of interest ▪ Off-label treatments will be mentioned Current research funding Patient-Centered Outcomes Research Institute (PCORI) What is New in NMO? Natalia Rost, MD Chair scientific committee AAN Neuromyelitis Optica (NMO) Neuromyelitis Optica Spectrum Disease (NMOSD) ▪ Inflammatory disorder of the central nervous system ▪ Predominantly involving optic nerves and spinal cord ▪ Severe demyelination and axonal damage ▪ Rare disease: 0.5-10/100,000, ~8,000 patients in the US ▪ Black > Asian > White ▪ Female > Male Flanagan et al., 2016 Bukhari et al. 2017 Hor et al. 2018 (Guthy-Jackson Charitable Foundation) Multiple Sclerosis vs NMO Pittock and Lucchinetti 2016 History 1894: Clinical case descriptions 2004: AQP4 antibody identified by Devic and Gault by Lennon, Weinshenker et al. Eugene Devic (1858–1930) Lancet2004; 364: 2106–12; Journal of Neuroinflammation 2013, 10:8 Diagnostic Criteria Wingerchuk et al. 2015 Myelin Oligodendrocyte (MOG) Antibody ▪ More common in men and whites ▪ Bilateral optic neuritis, caudal myelitis ▪ Better recovery compared to AQP4-Ab pos NMO ▪ MRI brain without NMO findings ▪ Assay now commercially available at Mayo Sato et al. 2014; van Pelt et al. 2016 Auto-Antibody to Aquaporin 4 Water channel protein in ▪ Astrocytic foot processes at the blood-brain barrier ▪ Spinal cord grey matter ▪ Periaqueductal and periventricular regions ▪ Mueller cells in the retina Amiry-Moghaddam and Otterson 2003 Bystander Oligodendrocyte Injury Tradtrantip et al 2017 Pathology Extensive demyelination Perivascular & parenchymal Complement activation Axonal injury, necrosis eosinophils & granulocytes rosette and rim pattern Jacob et al.
    [Show full text]
  • Nicole Trask, Pharmd, Planning for the 2019 Specialty Drug Spend
    Planning for the 2019 Specialty Drug Spend August 24, 2018 Nicole Trask, PharmD Clinical Consultant Pharmacist University of Massachusetts – Clinical Pharmacy Services Disclosure for Nicole Trask I have no actual or potential conflict of interest in relation to this presentation. Budget Impact Modeling for 2 ||August 24, 2018 the Specialty Drug Spend Objectives • Identify high-impact specialty pipeline drugs expected to reach the market in 2019-2020 • Summarize efficacy data for high-impact specialty pipeline drugs and indicate their anticipated place in therapy • Compare specialty pipeline drugs to currently available therapeutic options • Predict the budgetary impact of specialty pipeline drugs and discuss strategies to mitigate costs Budget Impact Modeling for 3 ||August 24, 2018 the Specialty Drug Spend Identifying High-Impact Drugs Two key drivers • Clinical impact • Efficacy/effectiveness • Therapeutic alternatives • Economic impact • Cost • Volume Budget Impact Modeling for 4 ||August 24, 2018 the Specialty Drug Spend Assessing Clinical Impact Clinical trial data Therapeutic alternatives • Placebo-controlled, • Me-too drug vs. head-to-head studies first-in-class • Adverse events • Market competition • Potential drug-drug • Consensus interactions guidelines • Target population • Patient willingness to use medication Budget Impact Modeling for 5 ||August 24, 2018 the Specialty Drug Spend Assessing Economic Impact Cost Volume • NADAC, AWP, WAC • Prevalence/incidence of • Supplemental rebate disease • Outcomes-based • Frequency of contracts administration • Value assessments • Duration of therapy (e.g., AHRQ, ICER, PCORI) AHRQ=Agency for Healthcare Research and Quality, AWP=average wholesale price, ICER=Institute for Clinical and Economic Review, NADAC=national average drug acquisition cost, PCORI=Patient-centered Outcomes Research Institute, WAC=wholesale acquisition cost Budget Impact Modeling for 6 ||August 24, 2018 the Specialty Drug Spend Other Factors Affecting Budget Impact Disease-specific Prescriber-specific • Chronic vs.
    [Show full text]
  • HY 2021 Results
    Roche HY 2021 results Basel, 22 July 2021 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Biologic Immunomodulators Pa Summary
    GEORGIA MEDICAID FEE-FOR-SERVICE BIOLOGIC IMMUNOMODULATORS PA SUMMARY Preferred Non-Preferred Arcalyst (rilonacept) Actemra Subcutaneous (tocilizumab) Benlysta subcutaneous (belimumab) Cimzia (certolizumab) Enbrel (etanercept) Cosentyx (secukinumab) Humira (adalimumab) Dupixent (dupilumab) Ilaris (canakinumab) Enspryng (satralizumab-mwge) Xeljanz (tofacitinib) Fasenra Pen (benralizumab autoinjector) Xeljanz XR (tofacitinib extended-release) Kevzara (sarilumab) Kineret (anakinra) Nucala Pen (mepolizumab autoinjector) Olumiant (baricitinib) Orencia Subcutaneous (abatacept) Otezla (apremilast) Rinvoq (upadacitinib) Siliq (brodalumab) Simponi (golimumab) Stelara (ustekinumab) Skyrizi (risankizumab) Taltz (ixekizumab) Tremfya (guselkumab) The drug names above include all available oral or subcutaneous formulations under the same primary name. LENGTH OF AUTHORIZATION: Varies NOTES: ▪ All preferred and non-preferred products require prior authorization. Intravenous (IV) formulations of the biologic immunomodulators are not covered under Pharmacy Services. ▪ The criteria details below are for the outpatient pharmacy program. If a medication is being administered in a physician’s office or clinic, then the medication must be billed through the DCH physician services program and not the outpatient pharmacy program. Information regarding the physician services program is located at www.mmis.georgia.gov. PA CRITERIA: Actemra Subcutaneous ❖ Approvable for members 2 years of age or older with a diagnosis of moderately to severely active polyarticular
    [Show full text]
  • Rett Syndrome: Coming to Terms with Treatment
    Hindawi Publishing Corporation Advances in Neuroscience Volume 2014, Article ID 345270, 20 pages http://dx.doi.org/10.1155/2014/345270 Review Article Rett Syndrome: Coming to Terms with Treatment Alan Percy Civitan International Research Center, University of Alabama at Birmingham, 1720 2nd Avenue South, CIRC 320E, Birmingham, AL 35294-0021, USA Correspondence should be addressed to Alan Percy; [email protected] Received 5 January 2014; Accepted 26 February 2014; Published 10 April 2014 Academic Editor: Ronald L. Klein Copyright © 2014 Alan Percy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Rett syndrome (RTT) has experienced remarkable progress over the past three decades since emerging as a disorder of worldwide proportions, particularly with discovery of the linkage of RTT to MECP2 mutations. The advances in clinical research and the increasing pace of basic science investigations have accelerated the pattern of discovery and understanding. Clinical trials are ongoing and others are planned. A review of these events and the prospects for continued success are highlighted below. The girls and women encountered today with RTT are, overall, in better general, neurologic, and behavioral health than those encountered earlier. This represents important progress worldwide from the concerted efforts of a broadly based and diverse clinical and basic research consortium as well
    [Show full text]
  • Pelizaeus-Merzbacher Disease (Pmd)
    PELIZAEUS‐MERZBACHER DISEASE (PMD) is a X‐linked disease that is transmitted from normal appearing carrier mothers to their sons. Each male born to these mothers has a 50/50 chance of being affected with PMD. Each female child born to them has a 50/50 chance of being a carrier herself. Having more than one affected child, with a disease that there is only 50/50 of, I know sounds impossible, but I did the same thing! You have to realize it's a 50/50 chance with every pregnancy. One way to possibly describe this is to take a deck of cards, remove all 4 aces. Let the 2 red ones represent females, the ace of hearts could represent a non‐carrier female, the ace of diamonds could represent a carrier female. Let the 2 black ones represent males, the ace of clubs could represent a non‐affected male, the ace of spades could represent an affected male. With each pregnancy you have a 1 in 4 chance of having an affected son. Turn the 4 cards face down and draw one, if it should be the ace of spades (affected male), you can't say, "I have already had my affected one", and exclude it from the next pregnancy. With each pregnancy you have to "draw" from all 4 "cards". This disease affects the myelin sheath, that insulates the nerves of the central nervous system. These nerve fibers, called axons, carry impulses from the brain to other parts of the body. The axons are similar to an electrical wire, the myelin is like insulation that covers them.
    [Show full text]
  • X-Linked Diseases: Susceptible Females
    REVIEW ARTICLE X-linked diseases: susceptible females Barbara R. Migeon, MD 1 The role of X-inactivation is often ignored as a prime cause of sex data include reasons why women are often protected from the differences in disease. Yet, the way males and females express their deleterious variants carried on their X chromosome, and the factors X-linked genes has a major role in the dissimilar phenotypes that that render women susceptible in some instances. underlie many rare and common disorders, such as intellectual deficiency, epilepsy, congenital abnormalities, and diseases of the Genetics in Medicine (2020) 22:1156–1174; https://doi.org/10.1038/s41436- heart, blood, skin, muscle, and bones. Summarized here are many 020-0779-4 examples of the different presentations in males and females. Other INTRODUCTION SEX DIFFERENCES ARE DUE TO X-INACTIVATION Sex differences in human disease are usually attributed to The sex differences in the effect of X-linked pathologic variants sex specific life experiences, and sex hormones that is due to our method of X chromosome dosage compensation, influence the function of susceptible genes throughout the called X-inactivation;9 humans and most placental mammals – genome.1 5 Such factors do account for some dissimilarities. compensate for the sex difference in number of X chromosomes However, a major cause of sex-determined expression of (that is, XX females versus XY males) by transcribing only one disease has to do with differences in how males and females of the two female X chromosomes. X-inactivation silences all X transcribe their gene-rich human X chromosomes, which is chromosomes but one; therefore, both males and females have a often underappreciated as a cause of sex differences in single active X.10,11 disease.6 Males are the usual ones affected by X-linked For 46 XY males, that X is the only one they have; it always pathogenic variants.6 Females are biologically superior; a comes from their mother, as fathers contribute their Y female usually has no disease, or much less severe disease chromosome.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • X Linked Adrenoleukodystrophy: Clinical Presentation, Diagnosis, and Therapy
    4 Journal of Neurology, Neurosurgery, and Psychiatry 1997;63:4–14 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.63.1.4 on 1 July 1997. Downloaded from REVIEW X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy Björn M van Geel, Johanna Assies, RonaldJAWanders, Peter G Barth Abstract that has its onset in adulthood, was first X linked adrenoleukodystrophy (X-ALD) reported in 1976.4 Now, at least six diVerent is an inherited disorder of peroxisomal phenotypes are recognised.5 Not only men are metabolism, biochemically characterised aVected: in the early 1980s it was shown that by accumulation of saturated very long female carriers are at risk for developing chain fatty acids. Accumulation of these neurological deficits as well.6 fatty acids is associated with cerebral In 1976 the accumulation of saturated very demyelination, peripheral nerve abnor- long chain fatty acids (VLCFAs) in brain lipids malities, and adrenocortical and testicu- and adrenal cortex of patients with X-ALD was lar insuYciency. The lowest estimated reported.78 In 1980 raised concentrations of birth incidence is one per 100 000. At least VLCFAs were shown in cultured skin 9 10 six phenotypes can be distinguished, of fibroblasts and in 1981 in plasma, thus Department of which the two most frequent are child- providing a reliable biochemical diagnostic Neurology, Academic hood cerebral ALD and adrenomyelo- test. In 1984 a defect in peroxisomal metabo- Medical Center, 11 neuropathy. The X-ALD gene has been lism was suggested, and shortly thereafter the University of defective enzyme activity in peroxisomal Amsterdam, PO Box identified, but thus far no relation between â-oxidation of VLCFAs was discovered.12 13 In 22700, 1100 DE genotype and phenotype has been found.
    [Show full text]
  • An Interleukin-6 Receptor-Blocking Therapy for Neuromyelitis Optica Spectrum Disorder
    Review Neuroimmunology Satralizumab: An Interleukin-6 Receptor-blocking Therapy for Neuromyelitis Optica Spectrum Disorder Norio Chihara,1 Riki Matsumoto1 and Takashi Yamamura2 1. Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Japan; 2. Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan euromyelitis optica spectrum disorder (NMOSD) is a relapsing inflammatory disease of the central nervous system in which even a single disease flare may result in persistent neurological disability. The core group of patients with NMOSD, characterized by Nprominent astrocyte pathology, has high levels of autoantibodies reactive to aquaporin-4 (AQP4), a water channel expressed on astrocytes. In these patients, activation of autoreactive T and B cells, production of AQP4 autoantibody (AQP4-Ab) and AQP4-Ab-mediated complement-dependent destruction of astrocytes are presumed be the critical events in the pathology. Recent clinical trials have shown the efficacy of therapeutic antibodies targeting complement C5, interleukin-6 receptor (IL-6R) and CD19+ B cells in patients with NMOSD, particularly those with AQP4-Ab seropositivity. Regarding the pathogenesis of NMOSD, prior studies have indicated that IL-6 promotes the activation of autoreactive T cells, prolongs the survival of AQP4-Ab-producing B cells and inhibits blood–brain barrier integrity. The results of two pivotal clinical trials showing the efficacy of satralizumab have firmly established the role of IL-6 and IL-6R signalling in the pathogenesis of AQP4-Ab-positive NMOSD. This review aims to evaluate the involvement of IL-6 in NMOSD and the potential of satralizumab, a humanized antibody against IL-6R, in the current and future practice of NMOSD.
    [Show full text]